{"disease":{"id":"thrombotic-thrombocytopenic-purpura","name":"Thrombotic thrombocytopenic purpura","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"rituxan","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"caplacizumab-yhdp","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CABLIVI","generic_name":"CAPLACIZUMAB-YHDP","company_name":"ABLYNX NV","drug_phase":"marketed","molecular_target":"von Willebrand factor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"ruxience","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"rituximab","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"caplacizumab","indication_name":"Thrombotic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Calibvi","generic_name":"CAPLACIZUMAB","company_name":"Ablynx Nv","drug_phase":"marketed","molecular_target":"von Willebrand factor","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Calibvi works by binding to von Willebrand factor, preventing it from interacting with platelets and forming blood clots."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT05950750","title":"Turkey Thrombotic Thrombocytopenic Purpura Disease Registry: National Multicenter Study","phase":"","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"Turkish Hematology Association","has_results":false},{"nct_id":"NCT05571774","title":"Construction of a Database for TTP","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT04985318","title":"Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT03369314","title":"Observational Study of the Use of octaplasLG®.","phase":"","overall_status":"COMPLETED","enrollment_count":263,"lead_sponsor_name":"Octapharma","has_results":false},{"nct_id":"NCT04981028","title":"The ConNeCT Study: Neurological Complications of TTP","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Liverpool University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT05876221","title":"Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura","phase":"","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"University of Cologne","has_results":false},{"nct_id":"NCT05389007","title":".German TTP-Registry (Thrombotic Thrombocytopenic Purpura)","phase":"","overall_status":"UNKNOWN","enrollment_count":156,"lead_sponsor_name":"Johannes Gutenberg University Mainz","has_results":false},{"nct_id":"NCT03605511","title":"TTP and aHUS in Complicated Pregnancies","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT06376786","title":"Italian iTTP Registry","phase":"","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Fondazione Luigi Villa","has_results":false},{"nct_id":"NCT02134171","title":"Early Predictive Factors of Cardiac and Cerebral Involvement in TMA","phase":"NA","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02878603","title":"Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT05568147","title":"Aspirin for Prophylaxis of TTP","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07429942","title":"A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04683003","title":"A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":77,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03237819","title":"Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":74,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04720261","title":"Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":58,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT03393975","title":"A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05468320","title":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT05262881","title":"A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Catholic University of the Sacred Heart","has_results":false},{"nct_id":"NCT07353099","title":"A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06794008","title":"BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06945861","title":"Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)","phase":"","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"University Hospital, Rouen","has_results":false},{"nct_id":"NCT03519672","title":"Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT06441578","title":"A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura","phase":"","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03187652","title":"A Prospective Study on the Long-Term Vascular Burden in Thrombotic Thrombocytopenic Purpura Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT05714969","title":"A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05135442","title":"Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT03922308","title":"Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04074187","title":"A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT02216084","title":"Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT06831058","title":"A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT04588194","title":"Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"David Gomez Almaguer","has_results":false},{"nct_id":"NCT01938404","title":"Octaplas Adult TTP Trial","phase":"","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Octapharma","has_results":false},{"nct_id":"NCT05785468","title":"A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)","phase":"","overall_status":"UNKNOWN","enrollment_count":1,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT05393999","title":"SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Imperial College Healthcare NHS Trust","has_results":false},{"nct_id":"NCT05770219","title":"Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Takeda","has_results":false}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}